Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

742 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
What are the factors associated with long-term glycaemic control in patients with type 2 diabetes and elevated glycated haemoglobin (≥7.0%) at initiation of second-line therapy? Results from the DISCOVER study.
Bonnet F, Chen H, Cooper A, Gomes MB, Ji L, Leigh P, Ramirez L, Shestakova MV, Shimomura I, Siddiqui A, Tang F, Vora J, Watada H, Khunti K. Bonnet F, et al. Among authors: shimomura i. Diabetes Obes Metab. 2021 Oct;23(10):2336-2343. doi: 10.1111/dom.14476. Epub 2021 Aug 2. Diabetes Obes Metab. 2021. PMID: 34212481
Carbohydrate-to-insulin ratio is estimated from 300-400 divided by total daily insulin dose in type 1 diabetes patients who use the insulin pump.
Kuroda A, Yasuda T, Takahara M, Sakamoto F, Kasami R, Miyashita K, Yoshida S, Kondo E, Aihara K, Endo I, Matsuoka TA, Kaneto H, Matsumoto T, Shimomura I, Matsuhisa M. Kuroda A, et al. Among authors: shimomura i. Diabetes Technol Ther. 2012 Nov;14(11):1077-80. doi: 10.1089/dia.2012.0109. Diabetes Technol Ther. 2012. PMID: 23101953
Rationale, design, and baseline characteristics of a trial for the prevention of diabetic atherosclerosis using a DPP-4 inhibitor: the Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A).
Katakami N, Mita T, Yoshii H, Onuma T, Kaneto H, Osonoi T, Shiraiwa T, Kosugi K, Umayahara Y, Yamamoto T, Yokoyama H, Kuribayashi N, Jinnouchi H, Gosho M, Watada H, Shimomura I; Collaborators on the Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis Trial. Katakami N, et al. Among authors: shimomura i. J Atheroscler Thromb. 2013;20(12):893-902. doi: 10.5551/jat.18333. Epub 2013 Aug 20. J Atheroscler Thromb. 2013. PMID: 23965491 Free article. Clinical Trial.
Sequential introduction and dosage balance of defined transcription factors affect reprogramming efficiency from pancreatic duct cells into insulin-producing cells.
Miyashita K, Miyatsuka T, Matsuoka TA, Sasaki S, Takebe S, Yasuda T, Watada H, Kaneto H, Shimomura I. Miyashita K, et al. Among authors: shimomura i. Biochem Biophys Res Commun. 2014 Feb 21;444(4):514-9. doi: 10.1016/j.bbrc.2014.01.083. Epub 2014 Jan 25. Biochem Biophys Res Commun. 2014. PMID: 24472553
Rationale, design, and baseline characteristics of a clinical trial for prevention of atherosclerosis in patients with insulin-treated type 2 diabetes mellitus using DPP-4 inhibitor: the Sitagliptin Preventive study of Intima-media thickness Evaluation (SPIKE).
Mita T, Katakami N, Shiraiwa T, Yoshii H, Onuma T, Kuribayashi N, Osonoi T, Kaneto H, Kosugi K, Umayahara Y, Yamamoto T, Matsumoto K, Yokoyama H, Tsugawa M, Gosho M, Shimomura I, Watada H. Mita T, et al. Among authors: shimomura i. Diabetol Metab Syndr. 2014 Mar 10;6(1):35. doi: 10.1186/1758-5996-6-35. Diabetol Metab Syndr. 2014. PMID: 24607023 Free PMC article.
742 results